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IntroDuCtIon
Positive surgical margins at radical prostatectomy for the treat-
ment of prostate cancer vary tremendously in the literature (4% 
to 45.2%) [1]. Their presence suggests that the primary tumor has 
not been completely excised. It may occur because prostate cancer 
extends outside the prostate to the margins of resection or because 
there was a disruption of the prostatic capsule and exposition of 
neoplastic glands. A PSM may also be caused by pathological arti-
fact (tissue trauma) during intraoperative retraction of the prostate 
or during the processing of the specimens. Given the multiple 
key worDs
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abstraCt
Introduction. RP (radical prostatectomy) technique 
continues the major treatment option for men with 
potential cure and life expectancy exceeding 10 years. 
The aim of the study is to assess the impact of PSM on 
BR (biochemical relapse), to identify PSM risk factors, to 
clarify the factors involved in BR in the absence of PSM.
Material and methods. Consultation of 171 medical-re-
cords from patients submitted to RRP (radical retropubic 
prostatectomy) between January/2000-December/2005. 
Mean-age: 64 yr. Mean – PSA (positive surgical margin): 
11.88 ng/ml. Clinical staging: 67.8% cT1, 32.2% cT2. GS: 
≤6 (66.1%), =7 (21.1%), 8-10 (12.3%). PS: pT0 1.2%, pT2 
50.3%, pT3a 36.3%, pT3b 12.9%, pT4 0.6%. pathologi-
cal Gleason score: ≤6 39.2%, =7 40.9%, 8-10 19.3%. 
RB definition was PSA ≥0.2 ng/ml. Adjusted Odds-Ratios 
with 95% confidence intervals (CI) were estimated 
through univariate logistic regression. 
results. There were PSM in 46 specimens, 28 had 
single PSM and 18 multiple PSM (≥2). BR occurred in 
57 patients (33.3%), with an average time after surgery 
of 23.5 months – 26 patients had PSM and 31 had not. 
Statistical significant results for BR in variables PSA, 
PS and PSM. Quadruples if PSM (p <0.0001), triples in 
single PSM (p = 0.01) and is 6x higher in multiple PSM 
(p = 0.001). Regarding factors that influence the pres-
ence of PSM, only PS ≥pT3a reach statistical significance 
(p <0.0001). Patients with BR but without PSM (54.38%), 
variables statistically significant were: initial PSA >10, 
(p = 0.029) and pathological Gleason score ≥8 with 
a risk nearly 4x higher than pathological Gleason score 
≤6 (p = 0.027).
Conclusions. Statistical risk analysis concluded that the 
presence of PSM in RRP is strongly influenced by PS 
≥pT3a. The presence of PSM and their number increase 
significantly the risk of BR compared to other factors. 
In the absence of PSM, the factors that seem to be cru-
cial and with greater impact on BR are initial PSA>10 
and pathological Gleason score ≥8.
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table 1. Clinical and pathological characteristics of the entire studied 
population.
age (median age = 64 yr.) no %
<50 2 1
50-60 33 19
60-70 98 58
>70 38 22
psa (median psa = 11.9 ng/dl) no %
<4 6 4
4-10 93 54
>10 72 42
Clinical staging (Cs) no %
cT1 116 68
cT2 55 32
gleason score of biopsy (gs) no %
≤6 113 66
7 36 21
8-10 21 12
Mucinous 1 1
pathological gleason score no %
≤6 67 39
7 70 41
8-10 33 19
Mucinous 1 1
pathological staging (ps) no %
pT0 3 2
pT2 93 54
pT3a 62 36
pT3b 12 7
pT4 1 1
positive surgicalmargins (psM) 46 27
Without PSM 125 73
biochemical relapse (br) 57 33
Early (≤3 years) 46 81
Late (>3 years) 11 19
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causes of PSM the associated BR rate is highly variable. Conflicting 
studies have been reported regarding the prognostic significance 
of multiple vs. solitary PSM´s, PSM at apical vs. other locations 
and extensive vs. focal PSM. Another controversial issue is the 
treatment of patients with a positive surgical margin after radical 
retropubic prostatectomy. Options include observation, radiation 
therapy and early hormone therapy. Making the appropriate choice 
should be based on an understanding of the risk of recurrence 
without treatment [2].
patIents anD MetHoDs
We conducted a consultation of 171 medical records from 
patients submitted to RRP between January 2000 and December 
2005 (6 years). The sample was evaluated concerning clinical 
patients data, tumor and tumor development (Table 1). The defi-
nition of PSM was the presence of prostate cancer cells touching 
the inked surface of the excised prostate gland. Lymph nodes 
status was not a criterion studied in this series. The mean age 
was 64.44 years (46-76). The mean PSA was 11.88 ng/ml (1.4-
42.3). Clinical staging (CS) was 67.8% CT1 and 32.2% CT2. The 
Gleason score of biopsy (GS) was divided between ≤6 (66.1%), 
equal to seven (21.1%) and 8-10 (12.3%). The pathological 
stage (PS) was pT0 in two cases (1.2%), pT2 in 86 (50.3%), pT3a 
in 62 (36.3%), pT3b in 22 (12.9%) and pT4 in one case (0.6%). 
Pathological Gleason score was ≤6 in 39.2%, equal to seven in 
40.9% and 8-10 in 19.3%. The definition of RB was the value of 
PSA ≥0.2 ng/ml. Adjusted Odds Ratios (OR) with 95% confidence 
intervals (CI) were estimated through univariate logistic regres-
sion to assess risk factors.
results
We obtained statistical significant results for BR in the vari-
ables PSA, PS and PSM (Table 2). There were PSM in 46 specimens 
(26.9%), 28 (61%) had single PSM and 18 (39%) multiple PSM (≥ 
2); 39 (85%) presented non-apical PSM and only seven (15%) were 
reported to have apical PSM (Table 3). BR occurred in 57 patients 
(33.3%) with an average time after surgery of 23.5 months (3-72). 
From the 46 patients with PSM only 26 patients had BR i.e. there 
were 31 patients with BR and without PSM (Table 4).
It was found that the risk of BR quadruples in patients with 
PSM (OR = 3.94 95% CI [1.94-8.02], p <0.0001), triples in single 
PSM (n = 28) (OR = 3.03 95% CI [1.30-7.06], p = 0.01) and is six 
times higher in patients with multiple PSM (n = 18) (OR = 6.06 
95% CI [2.10-17.52], p = 0.001) (Table 5).
Regarding factors that influence the presence of PSM (Table 6), 
only PS ≥pT3a reach statistical significance, being linked to a seven 
times higher risk than the lower stages (OR = 6.76 95% CI [3.12-
14.67], p <0.0001) (Table 7).
table 2. Influence of risk factors on BR
Variables b s.e. wald df sig. or
95% C.I. for or
lower upper
age .030 .029 1.123 1 .289 1.031 .974 1.091
psa 4-10 20.287 16408.555 .000 1 .999 646182073.676 .000 –
psa >10 20.899 16408.555 .000 1 .999 1192359778.808 .000 –
psa >10 .701 .330 4.523 1 .033 2.016 1.057 3.845
Clinical staging ct2 .359 .344 1.091 1 .296 1.432 .730 2.808
gleason score = 7 .054 .406 .018 1 .893 1.056 .476 2.341
biopsy ≥8 .693 .482 2.067 1 .151 2.000 .777 5.146
pathological =7 .212 .372 .325 1 .568 1.236 .597 2.562
gleason ≥8 .802 .446 3.230 1 .072 2.229 .930 5.343
pathological pt2 -.602 1.250 .231 1 .630 .548 .047 6.355
stage pt3a .564 1.251 .203 1 .652 1.758 .151 20.403
pt3b 1.030 1.358 .575 1 .448 2.800 .196 40.057
pt4 -20.510 40192.970 .000 1 1.000 .000 .000 –
pat. stage ≥pt3a 1.1193 .338 12.443 1 .000 3.297 1.699 6.397
psM 1.372 .362 14.323 1 .000 3.942 1.937 8.021
table 3. PSM population
positive surgical 
margins (psM) n = 46
  no %
Single 28 61
Multiple (≥2)  18 39
Apical 7 15
non-apical 39 85
BR 26 57
non-BR 20 43
table 4. Patients with BR and PSM
biochemical relapse 
(br)  n = 57
  no %
PSM 26 46
Without PSM 31 54
table 5. Influence of PSM on BR
b s.e. wald df sig. or
95% 
C.I. 
lower
or 
upper
PSM         1.372 0.362 14.323 1 .000 3.942 1.937 8.021
SInGLE 
PSM          
1.109 0.431 6.625 1 .010 3.032 1.303 7.057
MULTI-
PLE PSM 
(≥2)
1.802 0.541 11.092 1 .001 6.065 2.100 17.517
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In patients with BR but without PSM (54.38%), the variables 
that showed statistical significance were the initial PSA >10, with 
a 2.5 times higher risk (OR = 2.52 95% CI [1.10-5,78], p = 0.029) 
and pathological Gleason score ≥8 with a risk nearly four times 
higher than in pathological Gleason score ≤6 (OR=3.77 95% CI 
[1.16-12.21], p=0.027) (Table 8).
DIsCussIon
The Seminar Article written by Fleshner et al reviewing a total of 
39 cases series and ranging cohort´s sizes from 100 to 7,268 cases, 
reported a tremendous variation in the incidence of PSM and in the 
number of risk factors for it. The overall PSM rates varied from 4% 
to 45.2%. The risk factors included pathologic stage, tumor volume 
and prostate specific antigen (PSA) level, tumor grade, type of resec-
tion, surgical experience and pathologic processing/interpretation.
Rates for PSM vary according to pathologic stage. Generally, 
PSM rates in patients with organ-confined tumors (pT2) are lower 
than those with pT3 disease or higher. In our series the range of 
PSM in men with pT2 disease was 24%. Among men with pT3 
disease or higher the rate of PSM was 76%. We could reach statis-
tical significance in this variable. Patients with PS ≥pT3a showed 
to have almost seven times higher risk of PSM than the lower 
stages (OR = 6.76 95% CI [3.12-14.67], p <0.0001).
The pathologic grade, tumor volume and stage are highly corre-
lated, making it difficult to assess the multivariate impact of grade 
on PSM. It can generally be claimed that patients with higher-grade 
disease are at higher risk of PSM 3, 4. We did not find statistical sig-
nificance of pathological Gleason score as risk factor for PSM but in 
cases of BR without PSM, patients with pathological Gleason score 
≥8 had a risk nearly four times higher than in pathological Gleason 
score ≤6 (OR = 3.77 95% CI [1.16-12.21], p = 0.027).
There is a correlation between tumor volume, PSA and the 
presence of PSM in radical prostatectomy. These covariates were 
used in clinical practice in the 1990 in the form of the Partin tables 
5. Over the past decade, the value of PSA as a predictor of tumor 
table 6. Sub-populations with and without PSM
positive surgical Margins 
(psM)  n = 46
no %
without psM  
n = 125
no %
psa
≤4 0 0% 7 6%
4-10 24 52% 67 54%
>10 22 48% 51 41%
Clinical staging
cT1 32 70% 85 68%
cT2 14 30% 40 32%
gs biopsy
≤6 30 65% 82 66%
=7 8 17% 29 23%
8-10 8 17% 13 10%
pathological staging (ps)
pT0 0 0% 2 2%
pT2 11 24% 75 60%
pT3a 30 65% 32 26%
pT3b 4 9% 18 14%
pT4 1 2% 0 0%
pathological gleason
≤6 14 30% 67 54%
=7 21 46% 70 56%
8-10 11 24% 32 26%
surgeon total
BG 1 0 0% 1
ML 11 2 18% 9
MFC 3 2 67% 1
FR 26 6 23% 20
JF 29 10 34% 19
PC 24 3 13% 21
JV 27 9 33% 18
FF 31 9 29% 22
CG 7 2 29% 5
CP 12 3 25% 9
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volume has come into question owing to stage migration, exten-
sive prostate biopsy strategies, and lower thresholds for biopsy. 
Stamey et al have shown that PSA >12 ng/ml is not associated with 
tumor volume, extra prostatic extension (EPE) or PSM [6]. Others 
have contradicted these findings [7]. Recent data have shown that 
the tumor volume still remains a predictor of PSM in the more 
recent era of prostate cancer detection and treatment [8]. We did 
not have statistical significance with the variable PSA.
The experience and technical quality of the surgeon perform-
ing the RRP is increasingly being recognized as an independent 
predictor of PSM and BR [9]. Like many other medical procedures, 
this phenomenon is volume outcome associated, however, large 
cohorts of low volume, well-performing surgeons exist as well 
as high-volume poor performing surgeons [9]. Vickers et al, 
in a recent paper, demonstrated that approximately 250 radi-
cal prostatectomies (PR) were necessary to achieve a low-rate 
of PSM nine nine and that fellowship trained surgeons seem 
to acquire these skills better than those who are non-fellowship 
trained [10]. In our series, probably because of the lower num-
ber of interventions done by each surgeon, we could not found 
statistical differences between them. Further research is needed 
in order to better understand the interactions between patient 
selection, specific intraoperative maneuvers, capsular incision, 
and outcome following PR.
A PSM in the radical prostatectomy impacts on outcome in the 
form of biochemical relapse, in the use of salvage therapies and 
perhaps in mortality. The impact of PSM on BR is well accepted 
among patients with ECE. The implications of BR on additional out-
table 7. Factors that influence the presence of PSM 
Variables b s.e. wald df sig. or
95% C.I. for or
lower upper
psa            <4 .284 2 .868
 4-10 20.176 16408.728 .000 1 .999 578680957.615 .000 .
              >10 20.362 16408.728 .000 1 .999 696875597.651 .000 .
           >10 .272 .347 .613 1 .434 1.312 .665 2.590
Clinical staging    ct2 -.073 .373 .038 1 .845 .930 .447 1.933
gs biopsy    ≤6 .986 2 .611
                     =7 -.327 .452 .525 1 .469 .721 .297 1.747
                   ≥8 .267 .509 .276 1 .599 1.306 .482 3.542
pathological stage   
≥pt3a 1.911 .395 23.379 1 .000 6.761 3.116 14.672
pat. gleason  ≤6 2.421 2 .298
                  =7 .484 .398 1.479 1 .224 1.622 .744 3.539
                   ≥8 .685 .478 2.048 1 .152 1.983 .777 5.064
table 8. Risk factors that influence BR without PSM 
Variables b s.e. wald df sig. or
95% C.I. for or
lower upper
age .022 .037 .355 1 .551 1.022 .951 1.098
psa > 10 .923 .424 4.750 1 .029 2.517 1.097 5.775
Clinical staging       .209 .437 .230 1 .632 1.233 .524 2.902
gs biopsy      ≤6 4.915 2 .086
                  =7 .181 .513 .124 1 .725 1.198 .439 3.271
  ≥8 1.326 .600 4.879 1 .027 3.765 1.161 12.206
pathological stage pt0 5.759 3 .124
pt2 -.648 1.255 .267 1 .606 .523 .045 6.117
pt3a -.405 1.291 .099 1 .753 .667 .053 8.372
pt3b 1.204 1.426 .713 1 .398 3.333 .204 54.532
pt0 2.087 2 .352
pt2 -.648 1.255 .267 1 .606 .523 .045 6.117
≥pt3a -.038 1.270 .001 1 .976 .963 .080 11.614
pat. gleason           ≤6 5.150 2 .076
 =7 .568 .488 1.354 1 .245 1.765 .678 4.598
 ≥8 1.299 .573 5.142 1 .023 3.667 1.193 11.271
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comes are more controversial and statistically less significant. The 
reason for this is the relatively long natural history of BR in terms 
to metastatic disease (9 years on average) and death (14 years on 
average) [11]. In our series we saw that 43% of patients with PSM 
did not had PSA recurrence. These facts seem to be associated with 
false positivity of the pathology, extremely slow growing disease 
that never manifests and difficult area around the resection mar-
gin, which results in cellular death (by cauterization, desmoplasia 
or ischemia) [12].
On the other hand we tried to found which were the risk fac-
tors for BR that in the absence of PSM were responsible for the PSA 
recurrence. We found in these patients (31 of 57 patients, 54.38%) 
statistical significance for initial PSA >10, with a 2.5 times higher 
risk (OR = 2.52 95% CI [1.10-5,78], p = 0.029) and pathological 
Gleason score ≥ 8 with a risk nearly four times higher than in 
pathological Gleason score ≤6 (OR = 3.77 95% CI [1.16-12.21], 
p = 0.027) (Table 8). Since tumor grade, stage and tumor volume 
are often tightly correlated, it is not surprising that tumors that 
are high grade are more likely to fail than lower grade tumors, 
especially if margins are positive. Generally, tumors of high grades 
(Gleason 8-10) tend to fail more often than lower grade tumors.
The impact of PSM on mortality has only recently been 
assessed. Duke et al has shown that PSM is a predictor of death 
post-RP. Walther et al [13], Karakiewicz and colleagues [14] have 
reported a negative impact on overall survival among patients 
with T3 disease and PSM compared with patients with a negative 
surgical margin. Even though other factors may be responsible for 
this observation. It is evident that a PSM puts a man at higher risk 
for BR and one cannot die from prostate cancer without a BR.
What about the location of PSM? Typically and as is described 
in most of the literature they occur predominantly at the prostate 
apex or posterolaterally near the neurovascular bundle (nVB) and 
less frequently at bladder neck, base and anterior zone. The high 
rate of apical PSM seems to be related to the predisposition of the 
area to trauma, increasing the probability of ink touching tumor 
and the desire of the surgeon to have a long supramembranous 
urethra. The cone pathologic processing technique applied to this 
area is the best way to minimize pathologic artifacts. In our series 
we only found 15% of apical margins and 85% non-apical. In most 
series that have examined the impact of the apical PSM on BR, the 
tumor control is equivalent to that of an organ-confined tumor [5, 
16]. The bladder neck margins and its significance are more contro-
versial. Theoretically, the involvement of the bladder neck indicates 
pT4 disease and the majority of patients have also other PSM. Rare 
cases of PSM only at the bladder neck have been reported. Some 
series describe a higher risk of BR hereas other do not [16-20].
The impact of number and degree of margin positivity has 
been long realized as an important predictor of disease recurrence. 
Multiple studies describe that patients with multifocal margins are 
at higher risk for disease recurrence [21, 22]. We obtained in our 
series a probability four times higher of BR in patients with PSM 
(OR=3.94 95% CI [1.94-8.02], p <0.0001), three times higher in 
patients with single PSM (n = 28) (OR= 3.03 95% CI [1.30-7.06], 
p = 0.01) and six times higher in patients with multiple PSM (n=18) 
(OR = 6.06 95% CI [2.10-17.52], p = 0.001) (Table 5). An extensive 
margin involvement is also more predictive than a focally positive 
margin [21, 23].
Another issue of extreme relevance and very controversial 
that needs to be discussed is how to manage patients with PSM 
and other risk factors of BR? There is no doubt that PSM leads 
to a higher utilization of second therapies for prostate cancer, 
such as adjuvant radiotherapy (RT), salvage (RT) and androgen 
deprivation therapy. There are only two published randomized 
controlled trials of adjuvant RT in prostate cancer [24, 25]. The 
European Organization for Research and Treatment of Cancer 
(EORTC) 22911 randomized 1005 patients with pT3 disease at RP 
between adjuvant RT and a “wait and see” policy (that were rec-
ommended to have salvage RT only if they had local recurrence 
and not for PSA failure alone) [24]. The Southwest Oncology 
Group (SWOG) 8794 (national Cancer Institute of Canada, 
nCIC, PR-2) had a similar design – 425 men with pT3 disease 
were randomized to either adjuvant RT of the prostate bed or 
observation, with a median follow-up at the time of analysis of 
10.6 years [25]. These studies provided good evidence that RT 
after RP can reduce the risk of PSA failure and of local recur-
rence. However, the standard practice after RP has developed 
since the SWOG and EORTC studies that were designed in the 
1980’s. Specially, salvage RT is now given earlier, at the time 
of BR rather than when local recurrence is clinically palpable, 
leading to a significant improvement in the efficacy of sal-
vage treatment. Thus, the results provide a strong rationale for 
a comparison between adjuvant RT and the current standard of 
care, which is observation with early salvage RT for BR. We think 
that the trial Medical Research Council-national Institute of 
Canada (RADICALS), upcoming soon, will attempt to answer this 
question [26].
ConClusIons
Statistical risk analysis of the studied series concluded that the 
presence of PSM in RRP is strongly influenced by PS ≥pT3a and 
that the presence of PSM and their number increase significantly 
the risk of BR compared to other factors. In the absence of PSM, 
the factors that seem to be crucial and with greater impact on 
BR are initial PSA >10 and pathological Gleason score ≥8. It is 
important to consider initial PSA, pathological Gleason score and 
surgical margins status when making treatment decisions after 
radical prostatectomy.
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